Veritas In Silico
Tokyo
About Veritas In Silico
Veritas In Silico focuses on drug discovery by targeting messenger RNA (mRNA) through its proprietary in silico platform. The company aims to provide effective treatments for diseases that lack satisfactory options by harnessing the potential of mRNA as a drug target.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $12.0M
- Funding stage: IPO
- Last round: Series C (Dec 2021)
- Ticker: tyo:130A
- Website: veritasinsilico.com
- Phone: [email protected]
Industries & Categories
Business Information Systems, Cloud Data Services, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/veritas-in-silico-161273 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.